240 related articles for article (PubMed ID: 25816367)
1. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
Yun H; Xie J; Olumi AF; Ghosh R; Kumar AP
Oncotarget; 2015 May; 6(13):11600-13. PubMed ID: 25816367
[TBL] [Abstract][Full Text] [Related]
2. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.
Ganapathy M; Ghosh R; Jianping X; Zhang X; Bedolla R; Schoolfield J; Yeh IT; Troyer DA; Olumi AF; Kumar AP
Clin Cancer Res; 2009 Mar; 15(5):1601-11. PubMed ID: 19223508
[TBL] [Abstract][Full Text] [Related]
3. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Selga E; Noé V; Ciudad CJ
Biochem Pharmacol; 2008 Jan; 75(2):414-26. PubMed ID: 17945194
[TBL] [Abstract][Full Text] [Related]
5. Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.
Zhang Y; Li L; Wang J; Cheng W; Zhang J; Li X; Zhang Z; Gong J; Ghosh R; Kumar AP; Xie J
Mol Carcinog; 2017 Oct; 56(10):2200-2209. PubMed ID: 28485511
[TBL] [Abstract][Full Text] [Related]
6. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Nakajima Y; Akaogi K; Suzuki T; Osakabe A; Yamaguchi C; Sunahara N; Ishida J; Kako K; Ogawa S; Fujimura T; Homma Y; Fukamizu A; Murayama A; Kimura K; Inoue S; Yanagisawa J
Sci Signal; 2011 Apr; 4(168):ra22. PubMed ID: 21487105
[TBL] [Abstract][Full Text] [Related]
7. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
[TBL] [Abstract][Full Text] [Related]
8. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence.
Bedolla RG; Gong J; Prihoda TJ; Yeh IT; Thompson IM; Ghosh R; Kumar AP
PLoS One; 2012; 7(9):e44917. PubMed ID: 23028678
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland.
Gao S; Wang H; Lee P; Melamed J; Li CX; Zhang F; Wu H; Zhou L; Wang Z
J Mol Endocrinol; 2006 Jun; 36(3):463-83. PubMed ID: 16720717
[TBL] [Abstract][Full Text] [Related]
12. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
[TBL] [Abstract][Full Text] [Related]
13. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer.
Bauman DR; Steckelbroeck S; Peehl DM; Penning TM
Endocrinology; 2006 Dec; 147(12):5806-16. PubMed ID: 16959841
[TBL] [Abstract][Full Text] [Related]
14. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype.
Guerini V; Sau D; Scaccianoce E; Rusmini P; Ciana P; Maggi A; Martini PG; Katzenellenbogen BS; Martini L; Motta M; Poletti A
Cancer Res; 2005 Jun; 65(12):5445-53. PubMed ID: 15958594
[TBL] [Abstract][Full Text] [Related]
15. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
Raclaw KA; Heemers HV; Kidd EM; Dehm SM; Tindall DJ
Prostate; 2008 Nov; 68(15):1696-706. PubMed ID: 18726983
[TBL] [Abstract][Full Text] [Related]
16. ERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1.
Mak P; Li J; Samanta S; Mercurio AM
Oncotarget; 2015 Nov; 6(37):40247-54. PubMed ID: 26450901
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer.
Muthusamy S; Andersson S; Kim HJ; Butler R; Waage L; Bergerheim U; Gustafsson JÅ
Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20090-4. PubMed ID: 22114194
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.
Verras M; Lee J; Xue H; Li TH; Wang Y; Sun Z
Cancer Res; 2007 Feb; 67(3):967-75. PubMed ID: 17283128
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
